Medicago wins BARDA order for Ebola antibodies; Bayer to manufacture biotech's heart compound;

@FierceBiotech: Novartis bags a surprise approval for the blood cancer-treating panobinostat. Article | Follow @FierceBiotech

@JohnCFierce: Top story yesterday: UPDATED: Bristol-Myers bags IDO immunotherapy in $1.25B buyout of fledgling Flexus. Article | Follow @JohnCFierce

@DamianFierce: MD Anderson has a Houston Rockets sponsorship called "Moon Shot of the Night," because why not. Video | Follow @DamianFierce

> Canada's Medicago says it has won a BARDA order to produce three antibodies that would have a similar impact as Mapp Biopharmaceutical's Zmapp. Medicago plans to manufacture the antibodies in Canada for a primate study of ebola. Release

> Bayer HealthCare and Aronora announced a strategic alliance to manufacture Aronora's AB-022 compound for the treatment of cardiovascular diseases. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Medtronic works to boost neuromodulation with bladder control startup acquisition. Article | Follow @FierceMedDev

@VarunSaxena2: The 10 largest med tech M&A deals announced in 2014. Feature | Follow @VarunSaxena2

@EmilyWFierce: Turning to Twitter, MD Anderson doc launches campaign against cancer drug prices. Story | Follow @EmilyWFierce

> J&J adds $420M to legal stockpile to resolve all-metal hip implant suits. News

> Biotronik says its investigational nitinol stent performed well in clinical trials. Report

Pharma News

@FiercePharma: Baxter U.S. Selects Bannockburn, Ill., Facility as Location for Baxalta Global Headquarters. Release | Follow @FiercePharma

@CarlyHFierce: ICYMI: Canadian paper backpedals from Gardasil side effects story. Report | Follow @CarlyHFierce

> Baxter picks HQ for biopharma spinoff, and it's just up the road. Article

> Takeda makes an M&A move in Turkey. Report

> Actavis' buyout of Allergan could trigger $100M golden parachute for Pyott. Story

Biotech Research News

> MD Anderson team explores a combination approach against cancer metastasis. More

> Study: New antibody blocks dengue virus. Item

> UC San Diego group zeroes in on breaking a link between obesity and diabetes. Story

> Langer team offers up a hydrogel drug delivery vehicle at MIT. Report

> CRISPR project points to a new approach on Duchenne muscular dystrophy. Article

Pharma Manufacturing News

> Sun Pharma recalls epilepsy drug as dissolution woes continue. News

> Mylan bags rights to distribute Gilead's Sovaldi in India. Item

> Lupin plant hit with Form 483 but continues to rack up approvals. Report

> McKesson outed as company behind 340,000-sq-ft distribution hub in Iowa. Story

> India turns to small manufacturers for state-run generic supply biz. Article

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.